8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 26, 2018)

Filed April 26, 2018For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on April 26, 2018, to announce its first-quarter 2018 financial results. The primary focus of this filing is the release of their earnings performance and related financial condition for the period ending April 25, 2018. Investors should refer to the furnished press release (Exhibit 99.1) and supplemental information on the company's website (Exhibit 99.2) for detailed financial metrics, operational highlights, and management's commentary on the quarter's performance. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification and accessibility point for this crucial investor information. The press release and supplemental data are expected to cover key performance indicators such as revenue, earnings per share (EPS), and updates on the company's product pipeline and strategic initiatives. Investors are encouraged to review these exhibits to gain a comprehensive understanding of BMY's financial health and future outlook.

Key Highlights

  • 1BMY announced its first-quarter 2018 financial results on April 26, 2018, via an 8-K filing.
  • 2The filing incorporates by reference a press release detailing the Q1 2018 financial performance.
  • 3Supplemental financial information is also available on the company's website and incorporated into the filing.
  • 4Investors can access detailed financial results, including revenue and earnings, through the furnished press release.
  • 5The report indicates the company is providing transparency on its financial condition as of April 25, 2018.
  • 6This 8-K serves as the official notification of BMY's Q1 2018 earnings release.

Frequently Asked Questions

The detailed financial results are provided in the press release (Exhibit 99.1) furnished with this 8-K filing and in supplemental information available on the company's website at www.bms.com (Exhibit 99.2).

The main purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb's financial results for the first quarter of 2018.

No, the 8-K filing itself does not contain the detailed financial numbers. It incorporates by reference the press release and supplemental information where those details can be found.

Investors should look for key performance indicators such as total revenue, revenue by product/segment, cost of goods sold, operating expenses, net income, earnings per share (EPS), and any updates on the company's drug pipeline and strategic business developments.